Windhover.com | Medtech Insight | The RPM Report | Inteleos | EBI
Subscriber Username:   Password: Forgot Password?
Health Care Business Intelligence, Analysis, Insight - Windhover
Search


Receive Windhover's unique market insight fast with our free alert service 'Windhover's Update', including the latest abstracts and summaries from:

• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight


Sign up now


Elsevier Business Intelligence/Windhover
10 Hoyt Street
Norwalk, CT 06851
Tel: 203-838-4401


I-95 South:

Exit 16 (East Ave.). Take right at end. At 4th light, take left onto East Wall St. At 1st light, take right onto Main St. Take 2nd left onto Hoyt St. Windhover is second driveway on right. Door has blue awning.

I-95 North:


Exit 16 (East Ave.). Take left at end. At fifth light, take left onto East Wall St. At 1st light, take right onto Main St. Take 2nd left onto Hoyt St. Windhover is second driveway on right. Door has blue awning.

Merrit Parkway North:


Exit 39A (Route 7 Connector). Take Exit 1, and bear right at bottom of exit ramp. Make your first right onto Belden Ave.  At the second traffic light make a left onto Cross St.  Cross train tracks and make first right onto Hoyt Street.   Windhover's visitor lot is located on your left hand side, across from McMahon Ford's lot. Door has blue awning.

Merrit Parkway South:


Exit 40A (Route 7 / Main Avenue). At bottom of exit ramp, take a right onto Route 7 South (Main Ave.). Continue on Rt. 7 South to Route 123 intersection (Dunkin Donuts landmark on right). Bear left onto Route 123 South (still considered Main Ave.). Continue to intersection of 123 South and Route 1. Continue straight one more block, Hoyt Street is on right after Family Diner. Windhover's visitor lot is second driveway on right, door has blue awning.

The IN VIVO Blog

BIOWindhover/Pharmaceutical Strategic Outlook
February 23-25, 2010 · New York, NY

IN3 West + Investor Day
March 3-5, 2010 · Las Vegas, NV

IN3 Europe + Investor Day
April 28-30, 2010 · Paris, France

Interested in presenting at a Windhover conference?
Submit your idea here


Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. . . [MORE] (IN VIVO)

The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. . . [MORE] (Start-Up)

Stent Market Doldrums Push Interest Elsewhere
The new realities of the drug-eluting stent market are evident in recent sales results from the big competitors, driving many of them to branch into other higher growth areas. . . [MORE] (Medtech Insight)

The Future of Pharma: The Scale to Fail
The pharmaceutical sector saw a wave of major consolidation in 2009. There are a number of lessons to be learned from the M&A activity that can be applied to the New Year, including the increasing need to get bigger in order to absorb the R&D misses. . . [MORE] (The RPM Report)

Read more from the latest: IN VIVO, Start-Up, The RPM Report, Medtech Insight, "The Pink Sheet", "The Pink Sheet" DAILY, "The Rose Sheet", "The Tan Sheet", PharmAsia News, Pharmaceutical Approvals Monthly, and "The Gray Sheet".




Pharma Deals
  FDA Has Full Plate This Fall for Vaccines: More Than H1N1
  GSK Slides Away From Innovation
  The Billion Dollar REMS: Xenazine?
Device Deals
  Stroke Devices: Facing Challenges Head On
  Vascular Closure Devices at the Crossroads
  What New Her2 Tests Say about Personalized Medicine

Interested in subscribing? Click here.
Publications - Databases - Conferences - About Us - Contact Us - Help - The IN VIVO Blog - Company Profiles - Subscriber Login

Copyright © 2010, Windhover Information, Inc. An Elsevier company. All rights reserved.

Elsevier Business Intelligence